Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axumin PET for Glioblastoma Progression vs Pseudoprogression
NCT03990285Phase 1Completed
- Sponsor
- Ali Nabavizadeh
- Start
- Jun 2019
- Primary completion
- Nov 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Ali Nabavizadeh. Primary endpoint: Pseudoprogression or tumor progression by histopathology at 2 years. Started Jun 2019; status: completed.
Beyond the preview
Go deeper on NCT03990285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03990285.